Page last updated: 2024-09-04

atrasentan and pimonidazole

atrasentan has been researched along with pimonidazole in 1 studies

Compound Research Comparison

Studies (atrasentan)	Trials (atrasentan)	Recent Studies (post-2010) (atrasentan)	Studies (pimonidazole)	Trials (pimonidazole)	Recent Studies (post-2010) (pimonidazole)
358	41	108	382	22	116

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cho, H; Koutcher, JA; Li, XF; Ling, CC; Lupu, ME; Russell, J; Yang, KM	1

Other Studies

1 other study(ies) available for atrasentan and pimonidazole

Article	Year
Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model. Cancer biology & therapy, 2009, Volume: 8, Issue:20 Topics: Adenocarcinoma; Animals; Atrasentan; Colonic Neoplasms; Combined Modality Therapy; Etanidazole; Gadolinium DTPA; HT29 Cells; Humans; Hydrocarbons, Fluorinated; Hypoxia; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Nitroimidazoles; Perfusion; Pyrrolidines; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome; Xenograft Model Antitumor Assays	2009

Article

Year

Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.

Cancer biology & therapy, 2009, Volume: 8, Issue:20

Topics: Adenocarcinoma; Animals; Atrasentan; Colonic Neoplasms; Combined Modality Therapy; Etanidazole; Gadolinium DTPA; HT29 Cells; Humans; Hydrocarbons, Fluorinated; Hypoxia; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Nitroimidazoles; Perfusion; Pyrrolidines; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome; Xenograft Model Antitumor Assays

2009